Therapeutic Frontiers in Medicine 2026: Impulses for translational medicine

The Clusters4Future PROXIDRUGS, curATime, and CNATM jointly invited participants to the conference “Therapeutic Frontiers in Medicine: Mechanisms and Modalities 2026” in Bad Homburg. The event was aimed at researchers, clinicians, and professionals from industry, placing a strong focus on current developments in translational medicine.

Over a period of four days, more than 200 participants engaged in intensive exchange, including around 40 speakers. Discussions covered new therapeutic approaches, technological developments, and their translation into medical applications. The scientific program included two keynote lectures and eight session tracks, where the latest research findings were presented and discussed. The topics spanned new modalities and technologies such as proximity-inducing drugs for the targeted modulation of disease-relevant proteins, mRNA technologies, and artificial intelligence in medicine, as well as their application in addressing therapy resistance, inflammatory and cardiovascular diseases, and new strategies in cancer treatment. In addition, future challenges in translational medicine were addressed.

The lecture program was complemented by a poster exhibition featuring around 70 scientific contributions. Early-career researchers in particular took the opportunity to present their work and establish professional connections.

The conference highlighted the importance of cross-clustering between the three Clusters4Future PROXIDRUGS, curATime, and CNATM for Germany as a hub of innovation. Exchange formats like this help to strengthen the links between research, industry, and application, foster innovation networks, and accelerate the translation of new medical solutions into healthcare.

With its broad and diverse program, TFmed 2026 provided insights into current projects and developments and demonstrated how interdisciplinary collaboration can advance translational research. A continuation of TFmed is planned for 2028.